BIBProShares Ultra Nasdaq Biotechnology
Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.
ProShares · Since 2010 (16 years)
0.95%
#4471 out of 5,332 ETFs
$81M
#2936 out of 5,332 ETFs
0.60%
16 years
#783 out of 5,332 ETFs
Performance
1 Year
+69.5%
3 Years
+14.7%
5 Years
-2.4%
What's inside
Asset allocation
Sector breakdown
Top holdings
Risk profile
42.2%
High
-66.2%
Worst peak-to-trough loss
0.46
Below average
0.65
Moderate downside risk
Similar ETFs
Our take
Structural notes on how this fund behaves. Read our guide on the 6 warning signs.
Leveraged ETF — not a long-term hold
This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.
Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)
Why we flagged this: strategy=leveraged + leveraged_name_or_strategy
Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More
Data updated on 2026-05-05